Multiple Sclerosis Treatment Market to Reach $20 Billion by 2024

The main driver of growth in the Multiple Sclerosis (MS) market is the introduction of novel DMT products over the forecast period. Drugs targeting clinical unmet needs; such as improved efficacy, more convenient administration, or progressive MS approval; will increase treatment rates and drive market growth. The biggest barrier for growth in the MS market will be competition from generic/biosimilar products for key branded therapies. In particular, the launch of generic small-molecules will hamper future growth of the MS market. Considerable opportunity remains for products that meet the unmet needs in the MS market. A drug that prevents disease progression and the accumulation of disability would be viewed favourably. Additionally, targeting progressive MS will be an ongoing opportunity.

GlobalData’s PharmaPoint: Multiple Sclerosis – Global Drug Forecast and Market Analysis to 2024 report provides analysis of the multiple sclerosis treatment space across the ten major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India. It includes annualized market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.

 

The report includes:

 

  • Overview of MS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines

 

  • Annualised MS market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024

 

  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MS therapeutics market

 

  • Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

 

The MS market has experienced a paradigm shift with the launch of first-line oral DMTs and efficacious escalation therapies. Are you aware of the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period? Find out more!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s